| Not Yet Recruiting | CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma NCT06617286 | New York Medical College | Phase 1 / Phase 2 |
| Recruiting | European Project for ctDNA Detection as a Biomarker for Non-invasive Therapy Monitoring in Paediatric Classica NCT07356882 | Assistance Publique - Hôpitaux de Paris | — |
| Not Yet Recruiting | Phase II Trial of Anti-PD-1 Antibody Treatment and Radiotherapy in Early-stage Favorable Classic Hodgkin Lymph NCT06916416 | University of Cologne | Phase 2 |
| Active Not Recruiting | A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers NCT06870487 | Pfizer | Phase 1 |
| Recruiting | Sintilimab Plus AVD in Pediatric Low/Moderate Risk Hodgkin Lymphoma: A Phase II Study NCT06848569 | Sun Yat-sen University | Phase 2 |
| Recruiting | Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment NCT06563245 | Children's Cancer Group, China | Phase 2 / Phase 3 |
| Recruiting | Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma NCT04837859 | University of Cologne | Phase 2 |
| Recruiting | Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymp NCT04838652 | University of Cologne | Phase 2 |
| Withdrawn | Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory NCT04952584 | Baylor College of Medicine | Phase 1 |
| Recruiting | Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors NCT05934084 | Fondazione Italiana Linfomi - ETS | N/A |
| Completed | Microenvironmental Trial of Classical Hodgkin Lymphoma in Adolescents NCT06814860 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | — |
| Terminated | A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma NCT06018129 | Genmab | Phase 1 / Phase 2 |
| Recruiting | A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's Lymphoma NCT05900765 | Sun Yat-sen University | Phase 2 |
| Terminated | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours NCT05714553 | NuCana plc | Phase 1 / Phase 2 |
| Recruiting | Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age NCT05404945 | University of Virginia | Phase 2 |
| Active Not Recruiting | Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy NCT05352828 | Tessa Therapeutics | Phase 1 |
| Recruiting | A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies NCT05362773 | MacroGenics | Phase 1 |
| Recruiting | Changing Paragidms In The Prognostic Assessment Of Hodgkin Lymphoma NCT06822855 | Azienda USL Reggio Emilia - IRCCS | — |
| Recruiting | Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma NCT04510636 | University Health Network, Toronto | Phase 2 |
| Completed | Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical NCT05008224 | Merck Sharp & Dohme LLC | Phase 2 |
| Unknown | PD-1 Inhibitor or PD-1 Inhibitor Plus GVD for Relapsed/Refractory CHL NCT04624984 | Sun Yat-sen University | Phase 2 |
| Completed | Immune Responses to COVID-19 Vaccination in Lymphoma Patients NCT04858568 | University Hospital Southampton NHS Foundation Trust | — |
| Terminated | Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma NCT04486391 | BeiGene | Phase 3 |
| Recruiting | Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas NCT04288726 | Baylor College of Medicine | Phase 1 |
| Completed | Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma NCT04318080 | BeiGene | Phase 2 |
| Unknown | Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgki NCT04342936 | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 |
| Terminated | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer NCT04254107 | Seagen Inc. | Phase 1 |
| Terminated | LITT and Pembrolizumab in Recurrent Brain Metastasis NCT04187872 | University of Florida | Phase 1 |
| Active Not Recruiting | Abscopal Effect of Radiotherapy and Nivolumab in Relapsed Hodgkin Lymphoma After Anti-PD1 Therapy NCT03480334 | University of Cologne | Phase 2 |
| Completed | Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refr NCT03652441 | University of Cologne | Phase 2 |
| Active Not Recruiting | Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymp NCT04067037 | Henan Cancer Hospital | Phase 2 |
| Active Not Recruiting | Itacitinib + Everolimus in Hodgkin Lymphoma NCT03697408 | University of Pennsylvania | Phase 1 / Phase 2 |
| Completed | Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hod NCT03331341 | University of Washington | Phase 1 / Phase 2 |
| Completed | Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma NCT03739619 | Emory University | Phase 1 / Phase 2 |
| Completed | Phase Ib of L-NMMA and Pembrolizumab NCT03236935 | The Methodist Hospital Research Institute | Phase 1 |
| Unknown | Study for Elderly (≥ 65 Years) Patients With Classical Hodgkin Lymphoma Undergoing CGA at Diagnosis NCT03552003 | Fondazione Italiana Linfomi - ETS | — |
| Completed | An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Re NCT03580564 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 2 |
| Terminated | Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cH NCT03471351 | Rhizen Pharmaceuticals SA | Phase 1 |
| Withdrawn | Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large NCT03205891 | M.D. Anderson Cancer Center | Phase 1 |
| Unknown | OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy NCT03527628 | King Abdullah International Medical Research Center | Phase 2 |
| Completed | B-CD30 + Hodgkin Lymphoma International Multi-center Retrospective Study of Treatment Practices and Outcomes NCT03327571 | Takeda | — |
| Unknown | PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untr NCT03226249 | Northwestern University | Phase 2 |
| Active Not Recruiting | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers NCT03212404 | Checkpoint Therapeutics, Inc. | Phase 1 |
| Completed | Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers NCT03190174 | Sarcoma Oncology Research Center, LLC | Phase 1 / Phase 2 |
| Completed | A Study of Tislelizumab as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma NCT03209973 | BeiGene | Phase 2 |
| Completed | Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation NCT02981914 | University of Chicago | EARLY_Phase 1 |
| Completed | Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma NCT03004833 | University of Cologne | Phase 2 |
| Unknown | Prospective Comparison Between FDG-PET/MR and FDG-PET/CT in Classical Hodgkin Lymphoma and DLBC Non-Hodgkin Ly NCT03042247 | Marco Picardi | — |
| Active Not Recruiting | Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma NCT02940301 | Ohio State University Comprehensive Cancer Center | Phase 2 |
| Active Not Recruiting | HD21 for Advanced Stages NCT02661503 | University of Cologne | Phase 3 |
| Completed | Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma NCT02824029 | Barbara Ann Karmanos Cancer Institute | Phase 2 |
| Completed | Detection and Prognostic Value of Recurrent XPO1 Mutations of Patients With Classical Hodgkin Lymphoma NCT02815137 | Centre Henri Becquerel | N/A |
| Unknown | Social Inequalities in the Participation and Activity in Children and Adolescents With Hodgkin-lymphoma NCT02808520 | Martin-Luther-Universität Halle-Wittenberg | — |
| Completed | Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents NCT02684708 | University of Giessen | Phase 3 |
| Completed | Bendamustine Study in Classical Hodgkin Lymphoma Patients Over 60 Treated by Prednisone, Vinblastine and Doxor NCT02414568 | The Lymphoma Academic Research Organisation | Phase 2 |
| Recruiting | A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475 NCT02332668 | Merck Sharp & Dohme LLC | Phase 1 / Phase 2 |
| Completed | Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma NCT02243436 | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Phase 1 / Phase 2 |
| Completed | Risk Adapted Beacopp Regimen for Standard and High Risk Hodgkin Lymphoma NCT00305149 | Rambam Health Care Campus | N/A |